: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union.
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : 125459
: Checking if the patient might "shed" or spread the virus/vector through secretions. : This guideline is a cornerstone for developers
The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459 The guideline, officially titled , provides a framework
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA.
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .